Skip to main content
. 2017 May 16;14(5):e1002299. doi: 10.1371/journal.pmed.1002299

Fig 2. Cumulative risk of P. vivax recurrence in all four treatment arms over the entire follow-up time.

Fig 2

AL, artemether-lumefantrine; AL+PQ, artemether-lumefantrine + primaquine; CQ, chloroquine; CQ+PQ, chloroquine + primaquine.